Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.
You may also be interested in...
Future Of Lilly’s Arxxant In Doubt
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.
Future Of Lilly’s Arxxant In Doubt
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.
Keryx Looks To Release Top-Line Sulonex Phase III Data Early Next Year
A 2008 launch of the first-in-class diabetic nephropathy treatment is possible.